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Abstract
Multiple studies have reported that Latina women in the U.S. are diagnosed with breast cancer at 
more advanced stages and have poorer survival than non-Latina White women. However, Latinas 
are a heterogeneous group with individuals having different proportions of European, Indigenous 
American and African genetic ancestry. In this study we evaluated the association between genetic 
ancestry and survival after breast cancer diagnosis among 899 Latina women from the San 
Francisco Bay Area. Genetic ancestry was estimated from single nucleotide polymorphisms from 
an Affymetrix 6.0 array and we used Cox proportional hazards models to evaluate the association 
between genetic ancestry and breast cancer-specific mortality (tests were two-sided). Women were 
followed for an average of 9 years during which 75 died from breast cancer. Our results showed 
that Individuals with higher Indigenous American ancestry had increased risk of breast cancer-
specific mortality [hazard ratio (HR): 1.57 per 25% increase in Indigenous American ancestry; 
95% confidence interval (CI): 1.08–2.29]. Adjustment for demographic factors, tumor 
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characteristics, and some treatment information did not explain the observed association [HR: 
1.75, 95%CI: 1.12–2.74]. In an analysis in which ancestry was dichotomized, the hazard of 
mortality showed a two-fold increase when comparing women with <50% Indigenous American 
ancestry to women with ≥50% [HR: 1.89, 95%CI: 1.10–3.24]. This was also reflected by Kaplan-
Meier survival estimates (P for Log-Rank test of 0.003). Overall, results suggest that genetic 
factors and/or unmeasured differences in treatment or access to care should be further explored to 
understand and reduce ethnic disparities in breast cancer outcomes.
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Introduction
The incidence of breast cancer varies by race/ethnicity, with higher rates in non-Latina 
White women than African American, Asian/Pacific Islander, Hispanic/Latina or American 
Indian/Alaskan native women (1, 2). Despite the lower risk of breast cancer among U.S. 
women from minority populations, their risk of mortality after diagnosis is higher compared 
to that of non-Latina White women (3–7). In particular, compared to non-Latina Whites, 
Latina women are diagnosed with more advanced cancer stage and have poorer survival 
after controlling for prognostic factors (i.e., disease stage, age, tumor histology and 
treatment) (3, 8). Some studies have suggested that differences in survival may be explained 
by differences in socioeconomic status and access to care through their effects on disease 
stage at diagnosis and other tumor characteristics, as well as through direct effects on 
survival (4–7). However, most studies have not considered the well-known genetic 
heterogeneity among people within each racial/ethnic group.
Latinos have substantial genetic variation in terms of European, Indigenous American and 
African ancestry (9–12). In California, the majority of Latinos originates from Mexico and 
from Central America and has mostly European and Indigenous American ancestry. We 
have previously demonstrated an association between breast cancer risk and genetic ancestry 
among Latina women (13–15). In particular, among both U.S. Latinas and Mexican women, 
we found that higher European ancestry was associated with increased risk, whereas higher 
Indigenous American ancestry was associated with decreased risk (14, 15). This association 
is consistent with the epidemiological observation that non-Latina White women in the U.S. 
have higher incidence of breast cancer compared to both Latina and Native American 
women.
Previous studies suggested that breast cancer prognosis might have an inherited component 
(16, 17), and therefore exploring the relationship between genetic ancestry and breast 
cancer-specific mortality among women of mixed European, Indigenous American and 
African ancestry could provide important insights. Given that breast cancer mortality among 
Latinas is higher compared to non-Latina Whites, we hypothesized that Indigenous 
American ancestry may be associated with increased breast cancer-specific mortality. We 
tested this hypothesis in a sample of 899 U.S. Latina women with breast cancer. We also 
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evaluated whether the association between genetic ancestry and breast cancer-specific 
mortality was explained by differences in socioeconomic status, education, body mass 
index, family history of breast cancer, place of birth, language use, age at cancer diagnosis, 
treatment received and tumor characteristics.
Materials and Methods
Samples
The San Francisco Bay Area Breast Cancer Study (SFBCS): This population-based case-
control study in Latinas, African-American, and non-Latina White women aged 35–79 years 
was conducted between 1995 and 2004. A detailed description is provided elsewhere (18, 
19). The present study includes samples from 333 Latina women genotyped using the 
Affymetrix 6.0 array.
Northern California site of the Breast Cancer Family Registry (NC-BCFR): This population-
based family study enrolled incident breast cancer cases aged 18–64 years and selected 
family members. Cases include all those with indicators of increased genetic risk (i.e., cases 
with early onset disease, bilateral disease, personal history of ovarian cancer, family history 
of breast or ovarian cancer) and a random sample of cases not meeting these criteria (20). 
The present study includes 594 unrelated female cases diagnosed from 1995–2003 and that 
were genotyped using the Affymetrix 6.0 array.
From a total of 927 women (333 from SFBCS and 549 from NC-BCFR), we excluded from 
all analyses 28 (3%) cases with missing data on patient characteristics.
The study was approved by the Institutional Review Board for Human Subjects at all 
institutions. All participants signed a written informed consent.
Data collection
Breast cancer cases for both studies were identified through the Greater Bay Area Cancer 
Registry, which also provided information on tumor characteristics (stage, grade, size, 
estrogen and progesterone receptor status) and treatment during the first four months after 
diagnosis. Through linkage with the cancer registry, vital status was obtained as of October 
31, 2011. Breast cancer-specific deaths were derived from the underlying cause of death on 
the death certificate based on ICD-9 (9174-175) or ICD-10 (C50) codes.
The two studies collected information on demographic and cultural background (e.g., place 
of birth, age at migration, language use), body size, and reproductive history, using similar 
structured questionnaires that were administered by trained bilingual and bicultural 
interviewers in Spanish or English (18, 19). Given that the study questionnaires did not 
collect Information on individual level socioeconomic status-related variables, except 
education, neighborhood level socioeconomic status was estimated using the Yost census-
based principal component analysis approach (21). Briefly, the Yost composite index is 
obtained by geocoding the individual’s residential address at diagnosis to a census block and 
assigning each individual a previously developed block-specific socioeconomic status index 
value. This index is based on a principal component analysis of census data on education, 
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income and occupation. The first principal component represents a single composite 
measure of socioeconomic status. This measure of socioeconomic status has been previously 
associated with breast cancer incidence and risk and has been reported to complement the 
effect of individual-level education (21–23).
We used available information on place of origin of self, parents and grandparents to create 
four region categories: Central America (Mexico, El Salvador, Guatemala, Honduras, 
Panama and Costa Rica), Caribbean (Puerto Rico, Cuba and Dominican Republic), South 
America (Venezuela, Colombia, Peru, Bolivia, Brazil, Argentina, Chile, Ecuador) and U.S. 
(which includes all individuals that self-identified as Latinas/Hispanic but responded “U.S.” 
or other category to the question about origin of self and of all parents and grandparents).
Estimation of individual genetic ancestry
We estimated global individual ancestry as the average locus-specific ancestry across 59,211 
loci for each individual. Locus-specific ancestry estimates obtained with the HAPMIX 
software (24) were available from a previous genome-wide genotyping effort described 
elsewhere (13).
Statistical Analysis
We used one-way analyses of variance or t tests to explore the associations between genetic 
ancestry and patient characteristics, tumor characteristics and treatment received. African 
ancestry did not follow a normal distribution and therefore was log transformed (natural 
logarithm) for statistical analyses.
We used multivariate Cox proportional hazards models to evaluate the association between 
Indigenous American ancestry and breast cancer-specific mortality. Follow-up time in years 
was calculated as the difference between date of last follow-up and date of diagnosis.
We first conducted an analysis with Indigenous American ancestry defined in the model as a 
continuous variable, which was scaled so that the coefficient from the Cox model would 
reflect the effect on survival for each 25% increase in Indigenous American ancestry. Based 
on prior knowledge about possible prognostic factors, the analyses were adjusted for 
neighborhood socioeconomic status (continuous), education (<8 years, 8–11 years, high 
school graduate, and some college or higher), body mass index (<30, ≥30 kg/m2), family 
history of breast cancer in first-degree relatives (yes, no), place of birth [foreign-born (yes, 
no) and region of origin (Central America, Caribbean, South America, U.S.)], African 
ancestry (continuous), and first language spoken (English, English and another language, no 
English). We included tumor characteristics to test if the association between genetic 
ancestry and mortality could be due to the association between genetic ancestry and tumor 
stage (localized, regional extension or nodes only, regional extension and nodes, remote 
extension), grade (highly differentiated, moderately differentiated, poorly differentiated or 
Undifferentiated), size (<20mm, >20mm) and hormone receptor status (ER+/PR+, ER+/PR
−, ER−/PR+ and ER−/PR). We also tested if the observed association could be due to 
differences in treatment received during the first four months after diagnosis [type of surgery 
(none, lumpectomy or mastectomy); radiation (yes, no), and chemotherapy (yes, no)].
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To further explore the association between genetic ancestry and breast cancer-specific 
survival we created a categorical ancestry variable with four categories (0–25%, 25–50%, 
50–75% and 75–100% Indigenous American ancestry) and used Kaplan-Meier survival 
estimates to visualize the ancestry effect. Based on the results of the Kaplan-Meier survival 
curves analysis, we conducted the Cox model analyses with ancestry defined as a 
dichotomous variable (<50% vs. ≥50% Indigenous American ancestry).
The program STATA 12.1 was used for analyses and all tests were two-sided (25).
Multiple Imputation
We imputed values for missing tumor stage, grade and hormone receptor status data in order 
to maintain the sample size when running the fully adjusted model. We used multiple 
imputation as theoretically described by Rubin (26) and implemented in the STATA 12.1 
software (25). Imputation is a simple Monte Carlo technique that replaces missing values 
with imputed values and combines statistics from analysis conducted with multiple sets of 
imputed data. This approach is appropriate if the missing values are missing at random, that 
is, the missing data values carry no information about probabilities of missingness. Data on 
tumor characteristics are systematically collected by the Greater Bay Area Cancer Registry 
and therefore “missing at random” is a reasonable assumption. We specified 50 imputed 
datasets to achieve appropriate levels of variation in our estimates and 1,000 iterations (10 
burn-in).
Results
Association between genetic ancestry and potential predictors for breast cancer-specific 
mortality
Indigenous American genetic ancestry was significantly higher among women diagnosed at 
age ≤50 years, those who had a lower level of education, did not speak English as their first 
language, were born outside the U.S., and had a low socioeconomic status (Table 1). 
Indigenous American ancestry was lower among women with family history of breast 
cancer and varied by region of origin, ranging from 16% among women of Caribbean origin 
to 42% among women from Central America. We did not observe significant differences in 
genetic ancestry between obese and non-obese women, women with different tumor 
characteristics (including the “missing” category), or by treatment received. We also 
investigated the association between African genetic ancestry and these variables. African 
ancestry was slightly lower among women with higher education and higher socioeconomic 
status, those born in the U.S., and those who spoke English as their first language. African 
ancestry was significantly higher among women of Caribbean origin (median of 12%) and 
lowest among women from South America (median of 5%).
Association between genetic ancestry and breast cancer-specific mortality
Indigenous American ancestry was statistically significantly associated with breast cancer-
specific mortality in an analysis only adjusted by study [hazard ratio (HR) per every 25% 
increase in Indigenous American ancestry = 1.57, 95%CI 1.08–2.29] (Table 2). In bivariate 
analyses of other possible predictors of breast cancer specific-mortality we observed a 
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higher hazard of mortality among women who were diagnosed at a younger age, had a 
higher tumor stage, higher grade, larger tumor size, hormone receptor negative tumors, had a 
mastectomy or no surgery instead of a lumpectomy, and those who received chemotherapy 
(Table 2). In the fully adjusted model only Indigenous American ancestry (HR per 25% 
increase in Indigenous American ancestry: 1.75, 95%CI 1.12–2.74), region of origin, tumor 
stage, tumor size, and type of surgery were statistically significantly associated with 
mortality (Table 3). Caribbean origin was associated with a statistically significant increased 
risk of mortality when compared to women of Central American origin (HR 3.62, 95%CI 
1.08–12.09) only in the fully adjusted model. In an analysis stratified by study, the results 
showed no evidence of heterogeneity (for NC-BCFR: HR 1.77, 95%CI 0.96–3.25; for 
SFBCS: HR 1.63, 95% CI 0.81–3.27, study-ancestry interaction p value 0.915).
We also ran the fully adjusted Cox model in a subsample of 545 individuals without missing 
data (47 breast cancer-specific deaths) to assess if the observed statistically significant 
association between Indigenous American ancestry and survival could be due to improper 
adjustment as a result of the imputation. The results of the analysis with a reduced set of 
samples showed no indication that the association between ancestry and survival might be 
due to improper adjustment when using imputed data (Unadjusted HR: 1.43, 95%CI 0.88–
2.33. Adjusted HR: 1.54, 95%CI 0.91–2.63).
We further explored the relationship between genetic ancestry and survival by categorizing 
genetic ancestry and conducting Kaplan-Meier survival estimates. We first conducted an 
analysis that included four ancestry categories: 0–25%, 25–50%, 50–75% and 75–100% to 
be consistent with the magnitude of the unit change defined for the continuous ancestry 
model. This analysis strongly suggested that there was no difference in survival between 
individuals with 0–25% and 25–50% Indigenous American ancestry but that survival 
differed between individuals within these two lower ancestry groups and the individuals 
with 50–75% and 75–100% Indigenous American ancestry (Log-rank test P value = 0.015) 
(Figure 1.A). To obtain a HR estimate that corresponded more closely with the observed 
results, we dichotomized genetic ancestry (<50% vs. >50% of Indigenous American 
ancestry) and found a HR of 1.89 (95%CI 1.10–3.24) (Log-rank test P value=0.003) (Table 
3 & Figure 1.B).
DISCUSSION
We found that among U.S. Latinas from Northern California, Indigenous American ancestry 
was significantly associated with breast cancer-specific mortality. The association remained 
statistically significant after adjustment for age at diagnosis, body mass index, family history 
of breast cancer, place of birth, African ancestry, language use, socioeconomic status, 
education, tumor grade, stage, size, hormone receptor status, and treatment received in the 
first four months after diagnosis. The adjusted hazard ratio for every 25% increase in 
Indigenous American ancestry was 1.75 (95%CI: 1.12–2.74). Kaplan-Meier survival 
estimates based on a categorized ancestry variable strongly suggested that the effect of 
ancestry was non-monotonic and that the difference in survival was most pronounced when 
comparing women with >50% vs. <50% Indigenous American ancestry. The results showed 
that the hazard of mortality was twice as large among women with approximately half their 
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genomes being of Indigenous American origin compared to women with less Indigenous 
American ancestry.
The association between genetic ancestry and survival in our study was in the expected 
direction based on the previously described increased risk of breast cancer mortality among 
U.S. Latinas compared to non-Latina Whites (3, 27, 28). The association persisted after 
adjusting for multiple prognostic factors, which is compatible with the hypothesis of an 
underlying genetic component linking genetic ancestry and mortality in Latinas. However, it 
is also possible that our model did not include all relevant prognostic factors, thus, a role for 
non-genetic factors cannot be discarded. Non-Latina Whites tend to have higher level of 
screening and adequate treatment compared to other racial/ethnic groups (29, 30). In 
previous studies, the disparity in outcomes between non-Latina Whites and other groups, 
including Latinas, have been explained by differences in access to care, socioeconomic 
status and level of education (29–32). In the present study, the disparity in outcome by 
genetic ancestry was still observed after controlling for socioeconomic status, education, 
language use, place of birth, and treatment received. However, access to care and adherence 
to treatment beyond the first four months after diagnosis might not be properly captured by 
these available variables. Hormone therapy is highly effective for women with ER-positive 
disease, but inadequate adherence may substantially reduce its efficacy (33, 34). 
Furthermore, the type of hormone therapy may impact outcome. For example, a randomized 
clinical trial showed that more patients who received neo-adjuvant therapy with aromatase 
inhibitors had complete or partial responses than patients who received tamoxifen (35). Due 
to lower socioeconomic status, education and other related factors, women with higher 
Indigenous American ancestry may have been prescribed aromatase inhibitors less 
frequently. Future studies should explore the possibility that these factors might mediate the 
relationship between genetic ancestry and breast cancer-specific mortality among U.S. 
Latinas.
An interesting observation is that even though region of origin was not associated with 
mortality in a bivariate model, Caribbean origin was statistically significantly associated 
with increased risk of mortality in a fully adjusted model. Reports using SEER data also 
found increased mortality among Latina breast cancer cases of Caribbean origin (36). This 
association should be explored in future studies.
Our study did not find a significant association between African ancestry and breast cancer-
specific mortality. African American women in the U.S. have significantly higher breast 
cancer mortality than any other group. We have previously reported that among African 
American women, those with higher European ancestry are more likely to be diagnosed with 
ER-positive breast cancer, which tends to have a better prognosis. However, the proportion 
of African ancestry in our sample was low (~8%), which decreased our power to confirm 
such an association.
Family studies among women of European descent have suggested that breast cancer 
prognosis might have an inherited component (16, 17). Several studies have reported 
associations between SNPs within candidate genes and breast cancer survival (37–40), but 
most variants investigated are of unknown functional significance, and few have been 
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confirmed (41, 42). Among genetic variants known to be associated with breast cancer 
susceptibility, only one locus in the TOX3 gene was associated with survival at a level of 
statistical significance (p<0.01) (41). These results suggest that breast cancer survival may 
be influenced by a set of genetic variants different from those influencing cancer risk 
susceptibility. Few genome-wide association studies have been conducted to date to identify 
genotypes associated with clinical outcomes such as cancer recurrence, or overall survival 
(43–45). Shu et al. (43) reported a variant in the RAD51L1 gene and one in a locus on 
chromosome 16 to be associated with all-cause mortality among breast cancer patients from 
Shanghai. They replicated their results among European women from the Nurses’ Health 
Study. One of the studies conducted among European women reported a SNP in the OCA2 
gene associated with all-cause mortality among women with estrogen receptor-negative 
tumors (44), but a second study conducted as part of the Cancer Genetic Markers of 
Susceptibility (CGEMS) Study, found no SNPs with a statistically significant association 
with breast cancer survival (46). A two-stage study among women with early-onset breast 
cancer in the United Kingdom reported a SNP associated with breast cancer-specific 
survival upstream of the ARRDC3 locus (45). The association between genetic ancestry and 
breast cancer-specific mortality among U.S. Latinas, after adjusting for multiple potential 
confounders, raises the possibility that genetic variants that affect survival might differ 
between populations. Recent results in other cancers, such as neuroblastoma (47) or acute 
lynphoblastic leukemia (48), support this possibility.
Our findings may also be due to differences in the subtype of breast cancer that occurs 
among women with higher Indigenous American ancestry vs. women with higher European 
ancestry. Although we did not detect any association between ER/PR status and genetic 
ancestry, there is substantial heterogeneity among ER-positive breast cancers that can be 
identified by a variety of gene expression and other molecular markers that is also associated 
with prognosis (49). It is possible that women with higher Indigenous American ancestry are 
at higher risk for one of the more aggressive ER-positive subset of tumors, or that women 
with higher European ancestry are at increased risk for a less aggressive ER-positive subset 
of tumors. We have previously demonstrated that Latina women with higher European 
ancestry are at higher risk for overall breast cancer. If women with higher European ancestry 
are at increased overall risk for breast cancer, but they are at particularly higher risk for a 
less aggressive subtype, this could account for both our current results and our previously 
reported results.
This is the first study looking at the relationship between genetic ancestry and breast cancer-
specific survival among U.S. Latinas. Replication of the observed association in an 
independent sample of Latinas should be of high priority. Given the relatively high survival 
of women who develop breast cancer, it has been a challenge to find a cohort of Latina cases 
with enough events to test the presently observed association. We had access to genetic 
ancestry estimates, ER/PR status, age at diagnosis and survival information for 335 women 
with breast cancer from the Multiethnic Cohort study (MEC). There were a total of 35 
deaths from breast cancer and an average of 6 years of follow up time. Even though the 
sample was small and we did not have information on many of the potential confounders, 
results were consistent with our findings (Unadjusted HR <50% vs. >50% Indigenous 
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American ancestry=1.52, 95%CI 0.69–3.35; HR adjusted for age at diagnosis and ER/PR 
status=1.45, 95%CI 0.65–3.24).
We observed that the probability of survival was slightly higher in the SFBCS than in the 
MEC. This difference is likely to be due to the smaller proportion of advanced stage disease 
patients represented in the study (~5%) compared to the expected proportion based on the 
general patient population (7–10%). However, this potential limitation of the study is 
unlikely to have affected the association between genetic ancestry and survival because our 
analyses showed that the association was independent of tumor stage, grade, tumor size or 
hormone status. When we limited the analysis to women with early stage disease, the HR for 
the <50% vs. ≥50% Indigenous American ancestry model was still 2.09 (P value 0.011), 
which was very similar to the HR of 2.05 for the complete data set.
In the U.S., Latinos are the largest and youngest minority group, accounting for 15% of the 
Nation’s total population. Currently, there are ~42 million Latinos in the U.S., not including 
residents of Puerto Rico. U.S. Latinas, despite their relatively low incidence of breast 
cancer, tend to be diagnosed at a young age, with aggressive tumors and are more likely to 
die from the disease than non-Latina White women. Our study explored the difference in 
breast cancer-specific survival among Latinas with different proportions of Indigenous, 
European and African ancestry. We showed that Latina women with ≥50% Indigenous 
American ancestry have twice the hazard of breast cancer-specific mortality than Latina 
women with <50% Indigenous American ancestry. This important disparity could be due to 
non-genetic factors that were unaccounted for in the present study or to genetic differences. 
Identifying novel genetic variants that are associated with survival in this population might 
contribute to the understanding of the biological mechanisms that lead to worse breast 
cancer prognosis in this group as well as to the development of new treatments. 
Identification of putative modifiable socioeconomic or cultural factors that affect breast 
cancer-specific survival among Latinas with high Indigenous American ancestry could lead 
to the elimination of the observed disparity.
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Figure 1. 
A) Kaplan-Meier survival plot comparing 899 U.S. Latina breast cancer patients in 4 
categories of Indigenous American (IA) ancestry (<25%, 25–50, 50–75, 75–100). The X and 
Y axes represent follow-up time in years and the percentage of survival, respectively. The 
associated log-rank p value is 0.015. B) Kaplan-Meier survival plot comparing 899 U.S. 
Latina breast cancer patients in 2 categories of Indigenous American (IA) ancestry (<50% & 
>50%). The associated log-rank p value is 0.003.
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Table 2
Bivariate Cox proportion hazards models evaluating the association between breast cancer-specific mortality 
and patient and tumor characteristics and treatment among U.S. Latina breast cancer cases a
Patient Characteristics Categories Hazard Ratio 95% CI P valueb
Indigenous American ancestry (25% unit) 1.57 1.08 – 2.29 0.019
African ancestry (25% unit) 0.57 0.15 – 2.03 0.375
Age at diagnosis (5 yrs) 0.85 0.76 – 0.94 0.003
Socioeconomic status (Yost Index) 0.86 0.66 – 1.12 0.262
Obese ≥30 kg/m2) No 1.0
Yes 1.28 0.80 – 2.04 0.301
Family history of breast cancer No 1.0
Yes 0.52 0.24 – 1.15 0.108
Foreign-born No 1.0
Yes 1.1 0.70 – 1.73 0.689
Region of origin Central America 1.0
Caribbean 1.1 0.44–2.76 0.833
South America 1.12 0.45–2.81 0.802
U.S. 0.77 0.38–1.56 0.470
Education <8 years 1.0
8 to 11 years 0.87 0.43 – 1.74 0.688
High school graduate 0.71 0.37 – 1.36 0.298
Some college or higher 0.69 0.37 – 1.28 0.236
Language first spoken Other language 1.0
English & other language 1.04 0.44 – 2.46 0.931
English 1.28 0.78 – 2.10 0.334
Clinical Characteristics
Stage, N=762 Localized 1.0
Regional extension or nodes 3.55 2.07 – 6.09 <0.001
Regional extension & nodes 7.09 2.86 – 17.63 <0.001
Remote extension 19.42 8.49 – 44.42 <0.001
Grade, N=807 Highly differentiated 1.0
Moderately differentiated 1.7 0.69 – 4.20 0.251
Poorly differentiated & Undifferentiated 2.83 1.19 – 6.74 0.019
Hormone receptor status, N=645 ER+/PR+ 1.0
ER+/PR− 2.59 1.38 – 4.88 0.003
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Patient Characteristics Categories Hazard Ratio 95% CI P valueb
ER−/PR+ 2.12 0.50 – 8.93 0.305
ER−/PR− 1.31 0.67 – 2.55 0.423
Tumor Size, N=700 ≤20mm 1.0
>20mm 3.53 2.04–6.10 <0.001
Surgery Lumpectomy 1.0
Mastectomy 2.57 1.58 – 4.16 <0.001
No surgery 7.88 2.72 – 22.78 <0.001
Radiation No 1.0
Yes 0.94 0.59 – 1.49 0.791
Chemotherapy, N=894 No 1.0
Yes 2.44 1.41 – 4.21 0.001
a
Based on 899 breast cancer cases and 75 deaths from breast cancer
bAll models were adjusted by Study
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Table 3
Cox proportion hazards evaluating the association between breast cancer-specific mortality and Indigenous 
American ancestry among U.S. Latina breast cancer cases a
Hazard ratios for Indigenous American ancestry Categories Hazard Ratio 95% CI P valueb
Unadjusted
Indigenous American ancestry (25% unit) 1.57 1.08–2.29 0.019
Indigenous American ancestry (Categorical) <50% 1.0
≥50% 2.05 1.26–3.34 0.004
Adjusted
Indigenous American ancestry + A 1.58 1.03–2.42 0.035
Indigenous American ancestry + A + B 1.76 1.13–2.73 0.012
Indigenous American ancestry + A + B + C 1.75 1.12–2.74 0.014
Indigenous American ancestry + A <50% 1.0
≥50% 1.88 1.12–3.17 0.017
Indigenous American ancestry + A + B <50% 1.0
≥50% 1.83 1.07–3.11 0.027
Indigenous American ancestry + A + B + C <50% 1.0
≥50% 1.89 1.10–3.24 0.021
Hazard ratios for covariates in the full model
Personal characteristics = A
Age at diagnosis (5 years) 0.95 0.83–1.08 0.413
Obesity (≥30kg/m2) No 1.0
Yes 1.29 0.76–2.19 0.337
Family history of breast cancer No 1.0
Yes 0.74 0.32–1.72 0.484
Socioeconomic status (Yost Index) 0.89 0.65–1.23 0.487
Education <8 years 1.0
8–11 years 0.73 0.32–1.67 0.459
High school graduate 0.73 0.33–1.60 0.430
Some college or higher 0.59 0.26–1.36 0.215
Language use Other Language 1.0
English & other language 2.10 0.70–6.30 0.188
English 2.37 0.99–5.64 0.052
Foreign-born No 1.0
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Hazard ratios for Indigenous American ancestry Categories Hazard Ratio 95% CI P valueb
Yes 1.17 0.51–2.67 0.717
African ancestry (25% unit) 0.40 0.07–2.29 0.301
Region of origin Central America 1.0
Caribbean 3.62 1.08–12.09 0.037
South America 1.22 0.45–3.30 0.695
U.S. 0.66 0.29–1.50 0.327
Tumor characteristics = B
Stage Localized 1.0
Regional extension or nodes 2.69 1.39–5.18 0.003
Regional extension & nodes 3.28 1.15–9.38 0.027
Remote extension 17.02 5.84–49.58 <0.001
Grade Highly differentiated 1.0
Moderately differentiated 1.12 0.43–2.91 0.816
Poorly differentiated and Undifferentiated 1.41 0.52–3.82 0.503
Hormone receptor status ER+/PR+ 1.0
ER+/PR− 1.55 0.80–3.00 0.196
ER−/PR+ 1.54 0.34–7.05 0.579
ER−/PR− 1.02 0.49–2.09 0.966
Tumor Size (mm) ≤20mm 1.0
>20mm 2.04 1.07–3.86 0.029
Treatment Information = C
Surgery Lumpectomy 1.0
Mastectomy 1.92 1.03–3.58 0.040
No surgery 3.47 0.90–13.39 0.071
Radiation No 1.0
Yes 1.24 0.68–2.27 0.483
Chemotherapy No 1.0
Yes 0.83 0.40–1.70 0.604
ER: Estrogen Receptor; PR: Progesterone Receptor
a
Based on 899 breast cancer cases and 75 deaths from breast cancer
bAll models were adjusted by study
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